4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
8.99
+0.60 (7.15%)
At close: Feb 6, 2026, 4:00 PM EST
8.82
-0.17 (-1.89%)
After-hours: Feb 6, 2026, 7:38 PM EST
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 227 employees as of December 31, 2024. The number of employees increased by 80 or 54.42% compared to the previous year.
Employees
227
Change
80
Growth
54.42%
Revenue / Employee
$529
Profits / Employee
-$921,485
Market Cap
458.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 227 | 80 | 54.42% |
| Jun 30, 2024 | 201 | 64 | 46.72% |
| Mar 31, 2024 | 171 | 34 | 24.82% |
| Dec 31, 2023 | 147 | 7 | 5.00% |
| Sep 30, 2023 | 144 | 4 | 2.86% |
| Jun 30, 2023 | 137 | -1 | -0.72% |
| Mar 31, 2023 | 137 | 0 | - |
| Dec 31, 2022 | 140 | 16 | 12.90% |
| Sep 30, 2022 | 140 | 19 | 15.70% |
| Jun 30, 2022 | 138 | 34 | 32.69% |
| Mar 31, 2022 | 137 | 49 | 55.68% |
| Dec 31, 2021 | 124 | 41 | 49.40% |
| Sep 30, 2021 | 121 | 43 | 55.13% |
| Jun 30, 2021 | 104 | 26 | 33.33% |
| Mar 31, 2021 | 88 | - | - |
| Dec 31, 2020 | 83 | - | - |
| Sep 30, 2020 | 78 | 21 | 36.84% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 368 |
| Prothena Corporation | 163 |
| Kyverna Therapeutics | 129 |
| Invivyd | 100 |
| Ocugen | 95 |
| Zevra Therapeutics | 59 |
| Tectonic Therapeutic | 51 |
| Eupraxia Pharmaceuticals | 33 |
FDMT News
- 21 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 24 days ago - 4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - 4DMT Provides Company Update and Anticipated Development Milestones for 2026 - GlobeNewsWire
- 7 weeks ago - 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript - Seeking Alpha
- 7 weeks ago - 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - GlobeNewsWire
- 2 months ago - 4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - 4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - 4DMT to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewsWire